glp-1 obesity drug news today 2025 Market Industry Trends and Global Forecasts Obesity GLP-1 Market

Understand about the investigational Alluvi Retatrutide 40 mg injection a GLP-1 + GIP + Glucagon triple-agonist studied for obesity

This article explores the science behind these agents.

Discover Ozempic alternatives for type 2 diabetes and weight loss, including GLP-1s and oral medications

Andrew Stokes received a grant from the Robert Wood Johnson Foundation analyze the real-word effects of this new class of appetite-suppressing therapies, as well as inequities in access to these medications.

In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.

Commonly prescribed GLP-1RAs: Exenatide (Byetta, Bydureon) Liraglutide (Victoza, Saxenda) Dulaglutide (Trulicity) Semaglutide (Ozempic, Wegovy, Rybelsus) Tirzepatide (Mounjaro) Study overview: What was investigated